AUS
NZ
UK
CA
USA
IND
Highlights
- FDA panel raises concerns over GSK’s Blenrep combinations
- GSK maintains confidence in Blenrep’s potential
- Global reviews for Blenrep continue despite US setback
GSK (LON:GSK), a major player in the pharmaceutical landscape and a constituent of the FTSE 100, recently encountered a regulatory hurdle in the United States concerning its cancer treatment, Blenrep (belantamab mafodotin-blmf). A panel of advisors to the US Food and Drug Administration (FDA) did not endorse the proposed benefit-risk profile for certain combinations of the drug intended for patients battling relapsed or refractory multiple myeloma.
The committee raised questions about the dosage regimens evaluated in clinical studies, resulting in a non-favorable opinion regarding the current evidence presented. While this outcome does not constitute a final decision, the FDA will factor in the advisory panel's feedback ahead of its upcoming Prescription Drug User Fee Act (PDUFA) decision scheduled later this month.
Despite the advisory vote, GSK has reaffirmed its belief in Blenrep's potential. The company emphasized its commitment to collaborating with the FDA during the ongoing review process. It also pointed to the continued high need for advanced treatment options that can offer extended survival benefits to individuals with this aggressive form of cancer.
Notably, the Blenrep combinations in question have already received approvals in several global markets, including the UK and Japan. These approvals were grounded in data from the DREAMM-7 and DREAMM-8 phase III clinical trials, which provided compelling clinical insights. The therapy's reception in these regions supports GSK's position that the treatment has meaningful value in the broader oncology treatment landscape.
In addition to the markets where it has already been approved, regulatory applications for Blenrep are currently under assessment in the European Union and China. These international efforts underscore GSK’s global strategy for advancing oncology therapies and addressing critical unmet medical needs.
As regulatory developments unfold, investor attention remains closely fixed on how the FDA’s final decision could shape GSK’s pipeline trajectory and oncology footprint. While the recent feedback introduces challenges in the US market, the broader clinical and regulatory landscape still holds considerable promise for Blenrep’s role in future cancer care strategies.
